July 11, 2018
A New York federal judge revealed Tuesday that she had granted Kirkland & Ellis LLP-backed Merus NV's bid to collect $10.5 million in costs and attorney and expert fees from Regeneron Pharmaceuticals Inc. in an infringement dispute over a genetically modified mouse patent, holding that the request was reasonable.
June 26, 2018
A New York federal judge has ordered Regeneron Pharmaceuticals Inc. to pay attorneys' fees to Kirkland & Ellis LLP-backed Merus NV for its litigation misconduct in an infringement dispute over a genetically modified mouse patent, noting the not yet publicly filed opinion is of "particular public interest."
March 26, 2018
Regeneron Pharmaceuticals Inc. must pay Kirkland & Ellis LLP-backed Merus NV attorneys' fees after engaging in "severe litigation misconduct" from the outset of infringement litigation over a patent for a genetically modified mouse, a New York federal judge ruled on Monday.
August 10, 2015
Regeneron Pharmaceuticals Inc. withheld materials from the U.S. Patent and Trademark Office in order to secure a patent for genetically modified mice, a New York federal judge has found, adding yet another obstacle to the company's infringement suit against Dutch-based Merus BV.